2Prof. Dr., Isparta Kariyer Göz Hastanesi Purpose: To evaluate efficacy and safety of combined intravitreal bevacizumab (IVB) injection and phacoemulsification (PE) intraocular lens implantation for patients with exudative type age-related macular degeneration (ARMD), in postoperative short term.
Materials and Methods: In this study 36 eyes of 36 exudative ARMD patients (M/F: 15/21, mean age: 70.2±5.7years) had PE with intraocular lens (IOL) implantation and IVB injection (0.1 ml; 2.5 mg) at the end of surgery were included. Efficacy and safety measures included corrected visual acuity (CVA), intraocular pressure (IOP) and central macular thickness (CMT). Ocular examinations were performed at preoperative, postoperative 1st day, 1st week and, 1st month.
Results: Preoperative CMT was 342.0±57.7 (mean±standard deviation) micron and postoperative 1st month control CMT was 275.4±38.8 micron. There was mean 66.5±26.1 micron decrease in CMT. Preoperative IOP was 18.2±1.1mm Hg and postoperative 1st month control IOP was 17.7±1.4 mmHg. There was mean 0.5±1.2 mm Hg decrease. Preoperative CVA was 1.6±0.9 Log Mar and postoperative 1st month control CVA was 0.9±0.9 Log Mar. There was mean 0.7±0.6 Log Mar decrease.
Conclusion: In short term, combined IVB and PE-IOL implantation was safe and effective for ARMD patients.
Keywords : Age-related macular degeneration, bevacizumab, phacoemulsification